The Exercise Research Every APOE4 Carrier Needs to Hear

Ep. 10 Chronic Stress, Cortisol & Alzheimer's Risk: The APOE4 Vulnerability No One Talks About

Chronic stress is one of the most underappreciated risk factors for Alzheimer's disease and for APOE4 carriers, the relationship between stress hormones and neurodegeneration is not just additive. It's amplified through a distinct biological mechanism that operates independently of every other pillar in your prevention protocol. In this episode, Sarah walks through three years of personal HRV data that told her something her protocol wasn't accounting for, the research on why APOE4 carriers are fundamentally more vulnerable to the effects of chronic cortisol elevation, and what the science actually supports when it comes to stress reduction and Alzheimer's prevention. This is also the episode where the show's format changes and why. This episode covers: what HRV actually measures and why longitudinal trends matter more than daily scores, the APOE4-specific stress vulnerability equation, the odds ratio for Alzheimer's from chronic stress that rivals almost every other modifiable risk factor, the mitochondrial mechanism that makes cortisol more damaging in APOE4 brains, what the FINGER trial found about who benefits most from lifestyle intervention, and what Sarah is currently exploring. Show Notes [https://raceagainstmind.com/episodes/chronic-stress-cortisol-apoe4-alzheimers-risk]

Ep. 9 The Perimenopause-Alzheimer’s Connection: HRT, APOE4, and Why Timing Changes Everything

Women account for two-thirds of all Alzheimer’s cases. For a long time, the explanation was simple: women live longer. But that doesn’t fully account for the gap. What the research is now pointing to is that something happens during the perimenopausal transition that changes the brain’s trajectory : and for APOE4 carriers, that transition isn’t just uncomfortable. It may be the highest-leverage window in the entire prevention timeline. And it has a closing date. Last summer I started getting headaches I’d never had before. I was waking at 4am again : but differently than the nocturnal glucose drops I tracked in Episode 4. My CGM showed flat lines. My mood in the week before my period was something my husband noticed before I did. My cycles were shortening. I got my hormones tested. Everything came back normal. A month later I tested again : and the numbers were completely different. That second test is when I stopped telling myself it was stress. This episode covers what I found when I went into the research, covering the neuroprotective role of estrogen and progesterone, the FSH finding that changes how the field thinks about hormonal risk, the critical window hypothesis, the WHIMS study and what it actually tested, why the breast cancer scare was driven by the wrong formulation, and what all of it means specifically for APOE4 carriers. Then what I personally did: two hormone panels, bioidentical progesterone in November, transdermal estradiol in January, and what happened. I’m 42. I’m a double APOE4 carrier. This is not a future episode topic anymore. Shownotes [https://raceagainstmind.com/episodes/perimenopause-alzheimers-hrt-apoe4]

Ep. 8 The Alzheimer's Risk Factor Hidden in Your Nightly Glass of Wine

I was having a glass of wine most nights when I got my Oura Ring. Not a lot, or so I thought. Within weeks the data told a different story. My HRV baseline runs in the nineties. On mornings after drinking, even one glass, it dropped to the thirties or forties. Every time. Without exception. That data started a three-year experiment I didn't plan to run. And on December 31st, 2024, I eliminated alcohol entirely. What I expected was clarity. What I got instead, and what eventually led me to the p-tau217 test, a reinfected root canal, and a completely different understanding of why a clean baseline matters, is the story this episode tells. The research on alcohol and Alzheimer's has shifted significantly in the last few years and most people haven't caught up to it. The apparent protective effect of moderate drinking has largely collapsed under methodological scrutiny. The 2025 ALBION study found that light-to-moderate drinkers had nearly three times the odds of amyloid-beta positivity compared to abstainers. Not heavy drinkers. People who would never describe themselves as having a drinking problem. For APOE4 carriers specifically, one prospective study found that drinking at least once a month was associated with seven times the dementia risk compared to never drinking. Same behavior. Completely different biological outcome depending on what's in your DNA. This episode covers what the research actually says, why the APOE4 picture is categorically different from the general population, what eighteen months of not drinking actually cost me socially, and the thing I least expected to learn about why elimination matters beyond optimization. Show Notes [https://raceagainstmind.com/episodes/alcohol-apoe4-alzheimers-risk]

Ep.7 Blueberries, Coconut Oil, and the Mediterranean Diet: What the Nutrition Research Actually Says

Someone told me to give my mom coconut oil after her Alzheimer's diagnosis. My mom couldn't remember I was pregnant at the time. The person meant well. The advice was wrong. And for someone with APOE4 genetics — which both my mom and I carry — it wasn't just wrong. It was potentially the opposite of what the research supports. That moment is where this episode starts. Because the problem isn't people giving bad advice. The problem is an information ecosystem built to capture attention rather than convey evidence. Confident nutrition claims travel faster than careful ones, and for APOE4 carriers specifically, some of what's circulating online isn't just unhelpful, it's working against you. This is the third and final episode in the Race Against Mind nutrition series. Episodes 5 and 6 covered the personal cholesterol arc and the APOE4 lipid mechanism. This episode covers the broader nutrition research: what the science actually says about coconut oil, MCT oil, blueberries, the Mediterranean diet, omega-3s, B vitamins, ketogenic diets, and more. What's signal, what's noise, and what the internet consistently gets wrong. The structure is deliberate: myths first, nuanced middle, then what actually has evidence. Because knowing what to be skeptical of makes the things that are genuinely supported land differently. If you've been eating well for years and wondering why nutrition advice keeps disappointing you — this episode is for you. Show Notes [https://raceagainstmind.com/episodes/alzheimers-nutrition-myths]

Ep. 6 APOE4, Cholesterol, and Alzheimer's Risk: What Your Lipid Panel Is Missing

In February of last year, I woke up with brain fog so severe I started researching how to get a brain scan. I was convinced I had amyloid accumulating. I wanted data, not reassurance. It turned out to be a reinfected root canal. But that fear led somewhere useful — to a p-tau217 baseline test and a consulting engagement with an Alzheimer's prevention company that finally gave me the answer I'd been missing for twenty years. Sitting down to write a research paper on cholesterol and Alzheimer's risk, something clicked: of course my cholesterol is high. My APOE4 genotype makes lipid handling harder. That's not a diet failure. That's a design problem. This episode is the science companion to Episode 5. Where Episode 5 was the lived experience of five years of dietary intervention that barely moved the needle, this episode is the explanation — why cholesterol is a fundamentally different problem for APOE4 carriers, what it actually does in the brain, and why the standard lipid panel isn't giving you the full picture. We cover: what APOE4 actually does to lipid transport, amyloid clearance, neuroinflammation, and tau vulnerability. Why ApoB matters more than LDL for APOE4 carriers — and what the garbage bag analogy actually means for your cardiovascular and brain risk. What Lp(a) is and why you need to test it at least once. Why the connection between cardiovascular risk and Alzheimer's risk isn't two separate conversations for people with this genotype — it's one. And why understanding the mechanism finally made the statin decision obvious. Sarah is six weeks into a statin as of this recording, with no post-statin labs yet. She also has a p-tau217 baseline in — and explains why one result doesn't tell you much, but a trend over time could tell you everything. Show Notes [https://raceagainstmind.com/episodes/apoe4-cholesterol-alzheimers-risk-what-lipid-panel-missing]